<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EZETIMIBE</span><br/>(e-ze-ti'mibe)<br/><span class="topboxtradename">Zetia, </span><span class="topboxtradename">Ezetrol <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent; antilipemic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Works at the lining of the small intestine inhibiting the absorption of cholesterol, but does not inhibit cholesterol synthesis
         in the liver or increases bile acid excretion. Thus it decreases the amount of intestinal cholesterol available to the liver.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers both total cholesterol and low-density lipid (LDL) cholesterol; its mechanism of action is complimentary to statins.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of primary hypercholesterolemia alone or with an HMG-CoA reductase inhibitor (statin); treatment of homozygous sitosterolemia
         as an adjunct to diet.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ezetimibe; concurrent use with HMG-CoA reductase inhibitor in patients with active liver disease or elevated
         serum transaminases; hepatic insufficiency; concurrent administration with fibrates; lactation; pregnancy (category C); children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild hepatic insufficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercholesterolemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give no sooner than 2 h before or 4 h after administration of a bile acid sequestrant such as cholestyramine.</li>
<li>Store at 15°30° C (59°86° F). Protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fatigue, arthralgia, back pain, myalgia, angioedema, myopathy. <span class="typehead">CNS:</span> Dizziness, headache. <span class="typehead">GI:</span> Abdominal pain, diarrhea. <span class="typehead">Respiratory:</span> Pharyngitis, sinusitis, cough.  <span class="typehead">Hematologic:</span> Thrombocytopenia.  <span class="typehead">Skin:</span> Rash. <span class="typehead">Other:</span> Hepatitis, pancreatitis, rhabdomyolysis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">bile acid sequestrants</span> (e.g., <b>cholestyramine</b>) may decrease absorption (give ezetimibe 2 h before or 4 h after these drugs); <b>cyclosporine</b> or <span class="classification">fibric acid derivatives</span> can significantly increase ezetimibe levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from the small intestine. <span class="typehead">Peak:</span> 412 h. <span class="typehead">Distribution:</span> Ezetimibe-glucuronide is 99% protein bound. <span class="typehead">Metabolism:</span> Extensively conjugated to an active glucuronide compound (ezetimibe-glucuronide). Metabolized in small intestine and liver. <span class="typehead">Elimination:</span> Primarily excreted in feces. <span class="typehead">Half-Life:</span> 22 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline and periodic lipid profile; periodic Hgb &amp; Hct and platelet count. Monitor baseline LFTs and when
            used with a statin, monitor periodic LFTs in accordance with the monitoring schedule for that statin.
         </li>
<li>Assess for and report unexplained muscle pain, especially when used in combination with a statin drug.</li>
<li>Monitor closely patients who take both ezetimibe and cyclosporine.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unexplained muscle pain, tenderness, or weakness.</li>
<li>Females should use effective methods of contraception to prevent pregnancy while taking this drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>